Characterisation of transgenic pigs expressing a human T cell-depleting anti-CD2 monoclonal antibody.

ABSTRACT:

Background

Pig islet xenotransplantation is a potential treatment for type 1 diabetes. We have shown that maintenance immunosuppression is required to protect genetically modified (GM) porcine islet xenografts from T cell-mediated rejection in baboons. Local expression of a depleting anti-CD2 monoclonal antibody (mAb) by the xenograft may provide an alternative solution. We have previously reported the generation of GGTA1 knock-in transgenic pigs expressing the chimeric anti-CD2 mAb diliximab under an MHC class I promoter (MHCIP). In this study, we generated GGTA1 knock-in pigs in which MHCIP was replaced by the β-cell-specific porcine insulin promoter (PIP), and compared the pattern of diliximab expression in the two lines.

Methods

A PIP-diliximab knock-in construct was pre

SUBMITTER: Salvaris EJ 

PROVIDER: S-EPMC10909556 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature